文献速递糖尿病

高亲和力ZnT8自身抗体电化学发光法改善1型糖尿病风险预测

High-affinity ZnT8 Autoantibodies by Electrochemiluminescence Assay Improve Risk Prediction for Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究开发电化学发光法(ECL)检测高亲和力ZnT8自身抗体(ZnT8A),并在三个队列中验证。在ASK筛查中,RBA法单一ZnT8A阳性者仅少数经ECL确认,ECL-ZnT8A对1型糖尿病的阳性预测值显著高于RBA法。

要点

  • ECL法检测的高亲和力ZnT8A对1型糖尿病风险预测价值优于常规RBA法。
  • RBA法单一ZnT8A阳性在人群中常见,但多数为低亲和力、低风险。
  • ECL确认的单一ZnT8A阳性者进展为临床1型糖尿病的风险高。

核心结论

  • RBA法检测的ZnT8A大部分为单一阳性且1型糖尿病风险低,而ECL法检测的ZnT8A为高亲和力且对1型糖尿病进展预测价值高。

主要发现

  • 在302例新诊断1型糖尿病患者中,RBA和ECL检测ZnT8A的阳性率均为62%。
  • ASK队列135名RBA-ZnT8A阳性者中,64名为单一ZnT8A阳性,其中仅9名经ECL确认阳性,这些为高亲和力并伴1型糖尿病风险增加。
  • ECL-ZnT8A对1型糖尿病风险的总体阳性预测值为87.1%,显著高于RBA-ZnT8A的53.5%(P < .001)。
  • DAISY队列2547名无其他胰岛自身抗体阳性的儿童中,11名经RBA检测为单一ZnT8A阳性,其中3名经ECL确认阳性,且这3名均进展为临床1型糖尿病。

临床怎么用

  • 对于RBA法单一ZnT8A阳性的非糖尿病个体,可采用ECL法检测高亲和力ZnT8A以更准确评估1型糖尿病进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Single ZnT8 autoantibody (ZnT8A) positivity by standard radiobinding assay (RBA) is commonly seen in nondiabetes population-based screening and the risk of progression to type 1 diabetes (T1D) in subjects with single ZnT8A is unknown. OBJECTIVE: Identify the risk of progression to T1D in individuals positive only for ZnT8A. METHODS: We developed an electrochemiluminescence (ECL) assay to detect high-affinity ZnT8A and validated it in 3 populations: 302 patients newly diagnosed with T1D, 135 nondiabetic children positive for ZnT8A by RBA among 23 400 children screened by the Autoimmunity Screening for Kids (ASK) study, and 123 nondiabetic children multiple autoantibody positive or single ZnT8A positive by RBA participating in the Diabetes Autoimmunity Study in the Young (DAISY). RESULTS: In 302 patients with T1D at diagnosis, the positivity for ZnT8A was 62% both in RBA and ECL. Among ASK 135 participants positive for RBA-ZnT8A, 64 were detected ZnT8A as the only islet autoantibody. Of these 64, only 9 were confirmed by ECL-ZnT8A, found to be of high affinity with increased T1D risk. The overall positive predictive value of ECL-ZnT8A for T1D risk was 87.1%, significantly higher than that of RBA-ZnT8A (53.5%, P < .001). In DAISY, 11 of 2547 children who had no positivity previously detected for other islet autoantibodies were identified as single ZnT8A by RBA; of these, 3 were confirmed positive by ECL-ZnT8A and all 3 progressed to clinical T1D. CONCLUSION: A large proportion of ZnT8A by RBA are single ZnT8A with low T1D risk, whereas ZnT8A by ECL was of high affinity and high prediction for T1D development.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Jia X, He L, Miao D, et al. High-affinity ZnT8 Autoantibodies by Electrochemiluminescence Assay Improve Risk Prediction for Type 1 Diabetes. J Clin Endocrinol Metab. 2021. PMID: 34343303. doi:10.1210/clinem/dgab575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。